News and Press Releases
Press releases
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Press ReleaseTMX Newsfile | May 4, 2026 5:22 PM EDT Toronto, Ontario–(Newsfile Corp. – May 4, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the ...
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Press ReleaseTMX Newsfile | Apr 13, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – April 13, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to ...
Theralase(R) Closes $CAN 2.66 Million Financing
Press ReleaseTMX Newsfile | Apr 10, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – April 10, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to ...
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
Press ReleaseTMX Newsfile | Mar 17, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – March 17, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company, dedicated to...
Theralase(R) Closes $1.1 M Non-Brokered Private Placement
Press ReleaseTMX Newsfile | Mar 10, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – March 10, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to ...
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Press ReleaseTMX Newsfile | Mar 9, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – March 9, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to th...
Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy
Press ReleaseTMX Newsfile | Mar 2, 2026 7:00 AM EST Theralase(R) Demonstrates Additive Anti-Cancer Effect in Bladder Cancer In-Vitro Model when Light-Activated Ruvidar(R) is Combined with Interferon Toronto, Ontario–(Newsfile Corp. – March 2, 2026) –...
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Press ReleaseTMX Newsfile | Feb 20, 2026 7:00 AM EST This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the past. Toronto, Ontario–(Newsfile Corp. – February 20, 2026) – Theralase® Tec...
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
Press ReleaseTMX Newsfile | Feb 10, 2026 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – February 10, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated ...
Theralase® Provides Update on Bladder Cancer Clinical Study
Press ReleaseInterim clinical data has exceeded the recommended guidelines of the International Bladder Cancer Group for complete response and duration of complete response Toronto, Ontario – February 4, 2026 Theralase® Technologies Inc. (“Thera...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
